Gubra and AbbVie enter license agreement on amylin analog for obesity
Gubra has entered into a license agreement with AbbVie to continue development and commercialisation of a potential best-in-class, long-acting amylin analog for the treatment of obesity.
Under the terms of the agreement, AbbVie will lead development and commercialisation activities of GUB014295 globally.
Gubra will receive USD 350 million in total upfront payment and will be eligible to receive up to USD 1.875 billion in development, commercial and sales milestone payments with tiered royalties on global net sales.
Plesner is grateful to have advised Gubra, together with Goodwin LLP, on this strategically important transaction.
Plesner's core team on the transaction included Thomas Holst Laursen, Mikkel Rostock-Jensen, Nikolai Seltoft, Emma Louise Teisen, and Aske Alexander Dilling Lundgren.